Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quanterix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quanterix's regulatory disclosures and financial reporting.
Quanterix Corp (QTRX) reported insider equity activity by Chief Technology Officer Michael Francis Miller. On August 31, 2026, 159 restricted stock units converted into 159 shares of common stock, and 48 of those shares were delivered or withheld at $2.67 per share for payment of exercise price or tax liability. The RSU award referenced in this filing was part of a 6,278-unit grant originally awarded on September 23, 2022, with vesting over four years.
Quanterix Corp (QTRX) director Jeffrey Thomas Elliott reported an exercise and conversion of restricted stock units (RSUs) into common stock. On August 19, 2026, 3,955 RSUs were converted into 3,955 shares of common stock on a one-for-one basis. Following the transactions, Elliott directly held 15,345 shares of common stock and 4,075 RSUs. The RSUs relate to a prior grant of 11,985 RSUs, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the August 19, 2024 grant date, respectively.
Quanterix Corp (ticker QTRX) reports that James Edward Gute Jr., its Chief Commercial Officer, has filed an initial statement of beneficial ownership of securities on Form 3. The filing shows no reportable holdings or transactions in Quanterix Corp securities as of this filing.
Quanterix Corp (QTRX) director William P. Donnelly reported the vesting and conversion of restricted stock units into common stock. On 2026-08-17, 2,802 restricted stock units converted into 2,802 shares of common stock on a one-for-one basis, eliminating that RSU position. Following this transaction, Donnelly directly holds 162,401 shares of Quanterix common stock.
Quanterix Corp’s Chief Technology Officer, Michael Francis Miller, reported multiple equity compensation transactions on August 15, 2026. He exercised or converted restricted stock units into 1,558 shares of common stock, with the RSUs converting into common stock on a one-for-one basis. In related transactions, 467 common shares were delivered or withheld at $2.59 per share for payment of exercise price or tax liability. The mix of RSU conversions and share withholdings results in a largely administrative change in Miller’s reported holdings rather than a market purchase or sale.
Quanterix Corp director William P. Donnelly, through trusts established by him and his spouse, reported two indirect open-market purchases of common stock. On August 12, 2026, the trusts acquired 27,155 shares at a weighted average price of $2.75 per share, in multiple trades between $2.58 and $2.95. On August 13, 2026, they acquired an additional 72,245 shares at a weighted average price of $2.93 per share, in trades between $2.85 and $3.13. In total, the trusts purchased 99,400 shares of Quanterix common stock in these transactions.
Quanterix Corp reported an updated ownership statement from Portolan Capital Management, LLC and its manager George McCabe. The reporting group beneficially owns 1,899,308 shares of Quanterix common stock, representing 4.02% of the outstanding class as of the stated date.
Portolan Capital Management, LLC holds these shares directly in its capacity as investment manager for various clients, and George McCabe is deemed to own them indirectly as Manager of Portolan. The reporting persons have sole voting and dispositive power over all 1,899,308 shares and no shared voting or dispositive power, and they characterize their position as ownership of 5 percent or less of the class.
Quanterix Corporation reported stronger top-line results but significantly higher losses for the quarter ended June 30, 2026. Revenue rose 34% to $32.9 million (six-month revenue $69.3 million vs. $54.8 million a year earlier), driven largely by the 2025 acquisition of Akoya Biosciences, which added spatial biology instruments and services. Legacy Quanterix product and service revenue declined amid weaker academic and pharma demand and a constrained capital spending environment.
Profitability was heavily impacted by non-cash charges. The company recorded a $26.9 million goodwill impairment in Q2 and a $19.3 million impairment of in‑process R&D earlier in 2026 tied to a terminated development agreement, leaving goodwill fully written off. Net loss was $48.9 million for Q2 and $66.5 million for the first half, with operating cash outflow of $23.2 million. Quanterix ended June with $44.2 million in cash and $49.4 million in marketable securities, and stockholders’ equity of $237.2 million.
Strategically, management is refocusing on research tools growth and Alzheimer’s diagnostics. The company submitted a 510(k) application for a multi‑analyte blood test for Alzheimer’s disease and is promoting its LucentAD Complete LDT, which has a Medicare reimbursement rate of $897 and new commercial coverage starting July 1, 2026. Integration of Akoya is substantially complete, with approximately $85 million of annualized cost synergies realized, while contingent earnouts related to prior acquisitions remain in place.
Quanterix Corporation reported second-quarter 2026 revenue of $32.9 million, up 34% from $24.5 million a year earlier, led by product and service growth. GAAP gross margin was 38.5%, while adjusted gross margin improved to 47.9%. The company recorded a net loss of $48.9 million versus $30.0 million, driven largely by a $26.9 million goodwill impairment related to the Akoya acquisition and other restructuring costs. Adjusted EBITDA loss narrowed to $10.0 million from $13.7 million, and adjusted cash usage in the quarter was $4.0 million.
Quanterix ended the quarter with $96.9 million in cash, cash equivalents, marketable securities and restricted cash, and has realized $85 million of annualized cost synergies from the Akoya integration. The company revised its 2026 outlook, cutting expected revenue to $142–148 million from $169–173 million, lowering its non-GAAP gross margin range to 48–50%, and pushing expected cash-flow breakeven to 2027 with a projected year-end 2026 cash balance of about $80 million and no debt. Operationally, Quanterix advanced its Alzheimer’s diagnostics strategy, including Anthem coverage for its Lucent AD® Complete test, new biomarker launches, and selection as a co-investigator in a major Parkinson’s biomarker program. The company also strengthened its leadership team, appointing Jim Gute as Chief Commercial Officer to improve commercial execution.
First Eagle Investment Management, LLC reported beneficial ownership of 2,753,165 shares of Quanterix Corp common stock, representing 5.8% of the class as of June 30, 2026. These shares are held with sole voting and sole dispositive power, with no shared voting or dispositive authority.
The First Eagle Small Cap Opportunity Fund, a registered investment company advised by First Eagle Investment Management, may be deemed to beneficially own 2,421,533 of these shares, representing 5.1% of Quanterix’s common stock. Clients of First Eagle Investment Management have the right to receive and direct the receipt of dividends and sale proceeds for these securities.